Mind Medicine | MunAiMarkets

Mind Medicine

Psychedelics

By Lorimer WilsonPosted September 1, 2024Tags: 4-methylenedioxymethamphetamine, anorexia nervosa, attention deficit hyperactivity disorder, autism spectrum disorder, DMT, MDMA, mebufotenin, Mind Medicine, post-traumatic stress disorder, postpartum depression, psilocybin, psychedelic stocks, PTSD, social anxiety disorder, treatment-resistant depression

Psychedelic Compound Drug Stocks DOWN 16% In August – Here’s Why

An Introduction The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come. By Lorimer Wilson Some Background Shares of clinical-stage companies developing treatments based on psychedelic compound-based drugs moved lower in early August after the...